# A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

> **NCT01137994** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT01137994
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-10
- **Primary completion:** 2016-12
- **Final completion:** 2018-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137994, "A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01137994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*